Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of biweekly doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple-negative (TN), HER2-neu-positive (HER2+), or locally advanced breast cancer (LABC): Preliminary results of a prospective, phase II, nonrandomized study
Autor: | A. Klitsa, C. Georgakopoulos, N. Desses, P. Thomou, G. Xepapadakis, M. Tsantekidou, M. Vassilaki, A. Sioulas |
---|---|
Rok vydání: | 2010 |
Předmět: |
Oncology
Cisplatin Cancer Research medicine.medical_specialty Cyclophosphamide business.industry medicine.medical_treatment medicine.disease Metastatic breast cancer Carboplatin Regimen chemistry.chemical_compound Breast cancer chemistry Internal medicine medicine Doxorubicin business Adjuvant medicine.drug |
Zdroj: | Journal of Clinical Oncology. 28:e11006-e11006 |
ISSN: | 1527-7755 0732-183X |
DOI: | 10.1200/jco.2010.28.15_suppl.e11006 |
Popis: | e11006 Background: PLcs are active in TN locally advanced and metastatic breast cancer. This study aims to assess efficacy and safety resulting from the addition of cisplatin or carboplatin to a st... |
Databáze: | OpenAIRE |
Externí odkaz: |